IRMD Iradimed Corp

IRADIMED CORPORATION Issues Urgent Medical Device Correction

IRADIMED CORPORATION Issues Urgent Medical Device Correction

Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set

WINTER SPRINGS, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use which can lead to reduced flow with the MRidium infusion pump resulting in subsequent inlet occlusion and alarm indication. The 1057 Syringe Adapter Set is a unique IV fluid administration set with a vented syringe adapter (disposable tubing), which allows for the delivery of IV fluids from syringes while on the Company’s infusion pump. The customer notification, which outlines the potential risks associated with the 1057 Syringe Adapter Set, lists the affected products, and the updated labeling provides specific actions users should take to identify any venting and infusion delivery issues before an unexpected inlet occlusion occurs.

Iradimed received five customer complaints of an unexpected inlet occlusion alarm resulting in the infusion being stopped, none of which were associated with injuries or death. Upon investigation, the Company identified a defective injection molded part that can limit the effectiveness of the syringe vent and result in this condition in an estimated 0.4% of recently manufactured 1057 infusion sets.

This action was taken voluntarily to maximize the safety of the device’s use and with the knowledge of the FDA. No other of the Company’s IV sets or disposables are involved, and the Company does not expect any material financial impact from this action.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only provider of a non-magnetic intravenous (“IV”) infusion pump system designed to be safe during MRI procedures. We were the first to develop an infusion delivery system that eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other unique features to deliver anesthesia safely and predictably and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other unique features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.

For more information, please visit .



Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
 
EN
24/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iradimed Corp

Iradimed Corp: 1 director

A director at Iradimed Corp sold 5,000 shares at 95.433USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

IRADIMED Announces Special Cash Dividend of $0.50 Per Share

IRADIMED Announces Special Cash Dividend of $0.50 Per Share ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the onl...

 PRESS RELEASE

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders ...

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026 Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance ORLANDO, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative magnetic resonance imaging (MRI)-compatible medical devices, today announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista. The ranking eva...

 PRESS RELEASE

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Resul...

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1...

 PRESS RELEASE

IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results C...

IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025 ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, . Once registered, a d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch